25.28 0.44 (1.77%) | 02-13 16:02 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 32.07 | 1-year : | 37.46 |
Resists | First : | 27.45 | Second : | 32.07 |
Pivot price | 25.5 ![]() |
|||
Supports | First : | 23.67 | Second : | 21.34 |
MAs | MA(5) : | 25.05 | MA(20) : | 25.12 ![]() |
MA(100) : | 28.39 ![]() |
MA(250) : | 21.58 ![]() |
|
MACD | MACD : | -0.6 ![]() |
Signal : | -0.8 ![]() |
%K %D | K(14,3) : | 37.7 ![]() |
D(3) : | 38.7 ![]() |
RSI | RSI(14): 45.5 ![]() |
|||
52-week | High : | 38.93 | Low : | 2.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LENZ ] has closed above bottom band by 41.2%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 25.46 - 25.62 | 25.62 - 25.76 |
Low: | 24.05 - 24.23 | 24.23 - 24.4 |
Close: | 25 - 25.27 | 25.27 - 25.53 |
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Thu, 13 Feb 2025
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.7% - Here's Why - MarketBeat
Thu, 06 Feb 2025
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Mon, 18 Nov 2024
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Wed, 06 Nov 2024
LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Tue, 22 Oct 2024
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - Yahoo Finance
Mon, 21 Oct 2024
Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 28 (M) |
Shares Float | 13 (M) |
Held by Insiders | 2.8 (%) |
Held by Institutions | 86.5 (%) |
Shares Short | 2,450 (K) |
Shares Short P.Month | 2,260 (K) |
EPS | -2.75 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 7.82 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -27.1 % |
Return on Equity (ttm) | -42 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -2.49 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -71 (M) |
Levered Free Cash Flow | -49 (M) |
PE Ratio | -9.23 |
PEG Ratio | 0 |
Price to Book value | 3.22 |
Price to Sales | 0 |
Price to Cash Flow | -9.76 |
Dividend | 7.21 |
Forward Dividend | 0 |
Dividend Yield | 28.5% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |